Product Description
Mechanisms of Action: ELA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: China | Korea
Approved Indications: None
Known Adverse Events: None
Company: ONO Pharm
Company Location: CHUO-KU OSAKA 541 JA M0
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Acute Lung Injury|Acute Respiratory Distress Syndrome|Other|Respiratory Distress Syndrome, Newborn
Phase 3: Acute Respiratory Distress Syndrome|Respiratory Distress Syndrome, Newborn|Acute Lung Injury|Sepsis
Phase 2: Acute Respiratory Distress Syndrome|Respiratory Distress Syndrome, Newborn|Acute Lung Injury|Shock, Septic|Hemostatic Disorders|Coronary Artery Disease|Myocardial Ischemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2500108967 |
ChiCTR2500108967 | N/A |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease|Respiratory Insufficiency |
2028-08-31 |
|||
ChiCTR2500099241 |
ChiCTR2500099241 | N/A |
Not yet recruiting |
Pneumonia|Respiratory Insufficiency |
2027-12-31 |
|||
ChiCTR2500106233 |
ChiCTR2500106233 | N/A |
Not yet recruiting |
Pancreatitis, Acute |
2027-12-31 |
|||
ChiCTR2500105020 |
ChiCTR2500105020 | N/A |
Not yet recruiting |
Sepsis |
2027-07-01 |
|||
ChiCTR2500110021 |
ChiCTR2500110021 | N/A |
Not yet recruiting |
Unknown |
2027-06-30 |
|||
ChiCTR2400086632 |
ChiCTR2400086632 | N/A |
Not yet recruiting |
Unknown |
2027-04-24 |
2024-07-08 |
Treatments |
|
ChiCTR2500107626 |
ChiCTR2500107626 | N/A |
Not yet recruiting |
Acute Respiratory Distress Syndrome |
2027-03-31 |
|||
ChiCTR2200059102 |
ChiCTR2200059102 | N/A |
Not yet recruiting |
Acute Lung Injury |
2027-03-01 |
|||
ChiCTR2400086486 |
ChiCTR2400086486 | N/A |
Not yet recruiting |
Acute Respiratory Distress Syndrome |
2026-12-31 |
2024-07-03 |
Treatments |
|
ChiCTR2500098962 |
ChiCTR2500098962 | N/A |
Not yet recruiting |
Acute Lung Injury |
2026-12-31 |
|||
ChiCTR2500101095 |
ChiCTR2500101095 | N/A |
Not yet recruiting |
Acute Respiratory Distress Syndrome |
2026-11-30 |
|||
NCT07196605 |
IAT-TOP 2 | N/A |
Not yet recruiting |
Ischemic Stroke |
2026-03-01 |
2025-09-30 |
Primary Endpoints|Treatments |
|
NCT06195267 |
PANDA | N/A |
Recruiting |
Aortic Diseases |
2025-12-31 |
2024-11-21 |
Patient Enrollment|Primary Endpoints|Start Date|Treatments|Trial Status |
|
ChiCTR2400092841 |
ChiCTR2400092841 | N/A |
Not yet recruiting |
Unknown |
2025-06-30 |
|||
NCT06387823 |
STAR | N/A |
Recruiting |
Acute Lung Injury|Respiratory Distress Syndrome, Newborn|Acute Respiratory Distress Syndrome |
2025-06-01 |
2024-05-14 |
||
NCT05672472 |
Yuting Li1 | N/A |
Unknown status |
Sepsis|Acute Respiratory Distress Syndrome|Acute Lung Injury|Respiratory Distress Syndrome, Newborn |
2025-01-10 |
2025-02-12 |
Primary Endpoints |
|
NCT05343338 |
IPIADSS | N/A |
Unknown status |
Acute Lung Injury|Respiratory Distress Syndrome, Newborn|Acute Respiratory Distress Syndrome|Respiratory Insufficiency |
2024-12-31 |
2025-01-03 |
Primary Endpoints|Treatments|Trial Status |
|
ChiCTR2400083364 |
ChiCTR2400083364 | N/A |
Not yet recruiting |
Lung Diseases, Interstitial |
2024-10-31 |
2024-04-23 |
||
ChiCTR2300074438 |
ChiCTR2300074438 | N/A |
Recruiting |
Acute Lung Injury |
2024-07-31 |
2023-08-08 |
Treatments |
|
NCT05697016 |
HX-B-2022083 | N/A |
Unknown status |
Respiratory Insufficiency|Acute Respiratory Distress Syndrome|Acute Lung Injury|Respiratory Distress Syndrome, Newborn|Respiratory Tract Infections|COVID-19 |
2024-01-03 |
2025-01-03 |
||
NCT07214103 |
SivelSep | P2 |
Not yet recruiting |
Shock, Septic|Hemostatic Disorders |
2032-12-31 |
2025-10-10 |
Primary Endpoints|Treatments |
|
NCT07118930 |
2025-K171-01 | P2 |
Recruiting |
Myocardial Ischemia|Coronary Artery Disease |
2027-07-31 |
2025-08-13 |
Primary Endpoints|Treatments |
|
NCT06276569 |
2023-LCYJ-MS-26 | P3 |
Completed |
Acute Respiratory Distress Syndrome|Respiratory Distress Syndrome, Newborn|Acute Lung Injury |
2025-04-30 |
2025-08-07 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT07156656 |
STOP | P4 |
Not yet recruiting |
Other |
2028-09-30 |
2025-09-06 |
Primary Endpoints|Treatments |
|
NCT04909697 |
TOAWSS | P4 |
Recruiting |
Acute Lung Injury|Acute Respiratory Distress Syndrome|Respiratory Distress Syndrome, Newborn |
2026-03-30 |
2025-05-03 |